All Formulary decision guide articles
View all stories of the same content type.
-
Formulary decision guideKlisyri▼ (tirbanibulin) 10 mg/g ointment
This formulary decision guide was developed from content provided by Almirall Ltd in a format developed by Guidelines in Practice. It was commissioned by Almirall Ltd, who carried out full medical approval to ensure compliance with regulations.
View prescribing and adverse event reporting information
UK-KLI-2100017 | Date of preparation: October 2021 -
Formulary decision guide
Sixmo®▼ (buprenorphine) 74.2 mg implant
Information intended for UK healthcare professionals only. This formulary decision guide was developed from content provided by Accord Healthcare Limited in a format developed by Guidelines in Practice.
View prescribing information and adverse event reporting information.
UK-03417
Date of preparation: October 2021 -
Formulary decision guide
Ipinnia® XL (ropinirole hydrochloride) prolonged-release tablets
This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-IPN-13 Date of preparation: September 2021 -
Formulary decision guide
Steglatro®▼ (Ertugliflozin)
This formulary decision guide was developed from content provided by MSD UK Ltd in a format developed by Guidelines in Practice.
View prescribing information and adverse event reporting
GB-STE-00433 | June 2021 -
Formulary decision guide
Xaggitin XL (methylphenidate hydrochloride) prolonged-release tablets
This formulary decision guide was commissioned by Ethypharm and developed from content provided by Ethypharm in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
For UK healthcare professionals only.
UK-XAG-20 Date of preparation: July 2021 -
Formulary decision guide
Trurapi▼ (insulin aspart 100 units/ml)
This formulary decision guide was developed from content provided by Sanofi Ltd in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
MAT-GB-2101070(v2.0) | Date of preparation: July 2021 -
Formulary decision guide
EleCare®
This formulary decision guide was developed from content provided by Abbott in a format developed by Guidelines in Practice.
UK—2100014 | Date of preparation: June 2021 -
Formulary decision guide
Soprobec (beclometasone dipropionate) pMDI
This formulary decision guide was developed from content provided by Glenmark Pharmaceuticals Europe Ltd in a format developed by Guidelines in Practice.
View prescribing information
PP-UK-SOP-0130 V2 March 2021 -
Formulary decision guide
PROSTAP® DCS (leuprorelin acetate)
This formulary decision guide was developed by Guidelines in Practice based on content and funding provided by Takeda UK Ltd. Information intended for healthcare professionals only.
View prescribing information here
C-APROM/UK/LEU/0075 February 2021 -
Formulary decision guide
Nutramigen* PURAMINO*
This formulary decision guide was developed from content provided by Mead Johnson Nutrition in a format developed by Guidelines inPractice.
RB-M-18261 October 2020 -
Formulary decision guide
Nutramigen* 1, 2 & 3 LGG®
This formulary decision guide was developed from content provided by Mead Johnson Nutrition in a format developed by Guidelines in Practice.
RB-M-18259 October 2020
